glp 1 dangers How Dangerous Is Gastroparesis? The Hidden Dangers of GLP-1
Description
While preclinical studies support this hypothesis, robust clinical evidence remains limited
The observed effect of food on empagliflozin pharmacokinetics was not considered clinically relevant and empagliflozin may be administered with or without food
Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice
In 2022, total Medicare expenditures on the GLP-1/GIP agonists were $5.7 billion
References 1.Bu T., Sun Z., Pan Y., Deng X., Yuan G
2024;326:C1203C1211
